Biotech Values

[DewDiligence]

Re: PFE and The Global Demographic Tailwind (from 3Q11 CC):

http://seekingalpha.com/article/304116-pfizer-s-ceo-discusses-q3-2011-results-earnings-call-transcript

In terms of highlights for the quarter, our Emerging Markets business had a strong quarter, delivering operational growth of 12% with solid performance in key countries such as China, Russia, Turkey and India.

I am pleased with the continued progress of our Established Products business to penetrate the growing generics market both in developed markets as well as within emerging markets. Close to $1 billion of the $3.2 billion in total revenues for Established Products…came from Emerging Markets.

…For China, for the quarter, our reported growth was 31% operational growth, 26% on a year-to-date basis… Also adding in on China and we maintained the #1 rank in the market in China of all multinationals and local Chinese companies. And our growth rate is outpacing the underlying growth. So China is a big anchor point for us in emerging markets and we're doing very well there.